BCM
TSBX

Bridgeway Capital Management’s Turnstone Biologics TSBX Stock Holding History

Bridgeway Capital Management’s Portfolio TSBX Stock Details TSBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24,900
Closed -$65.2K – 1317
2024
Q2 		$65.2K Sell
24,900
-35,000
-58% -$100K ﹤0.01% 1199
2024
Q1 		$157K Hold
59,900
– – ﹤0.01% 1145
2023
Q4 		$152K Buy
+59,900
New +$156K ﹤0.01% 1183

Other funds holding TSBX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Bridgeway Capital Management's TSBX Position: Q3 2024 in Review

Bridgeway Capital Management sold out of Turnstone Biologics (TSBX) in Q3 2024, closing a stake of 24,900 shares — an estimated $65.2K sold.

Bridgeway Capital Management first reported a position in TSBX in Q4 2023 and held it in 3 quarters. The position peaked at $157K in Q1 2024. 24 funds tracked by Wall St. Rank hold TSBX as of Q3 2024.

  • Bridgeway Capital Management reported no remaining Turnstone Biologics position as of Q3 2024 after selling out during the quarter.
  • Bridgeway Capital Management sold 24,900 Turnstone Biologics shares in Q3 2024, an estimated $65.2K.
  • Bridgeway Capital Management first reported a position in Turnstone Biologics in Q4 2023 and held it in 3 quarters.
  • Bridgeway Capital Management's Turnstone Biologics position peaked at $157K in Q1 2024.
  • 24 funds tracked by Wall St. Rank held Turnstone Biologics as of Q3 2024.

Based on Bridgeway Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.